Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open‑Label, Fixed-Sequence Trials in Healthy Subjects

BACKGROUND AND OBJECTIVES: Suvorexant is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by C...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Drug Investig
Prif Awduron: Wrishko, Rebecca E., McCrea, Jacqueline B., Yee, Ka Lai, Liu, Wen, Panebianco, Deborah, Mangin, Eric, Chakravarthy, Manu, Martinez-Cantarin, Maria P., Kraft, Walter K.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6929321/
https://ncbi.nlm.nih.gov/pubmed/30810914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-019-00764-x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg